Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,590,000 shares, a decrease of 69.5% from the November 15th total of 5,220,000 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average daily volume of 34,310,000 shares, the short-interest ratio is presently 0.0 days.

Tonix Pharmaceuticals Trading Up 5.1 %

Shares of NASDAQ TNXP traded up $0.01 during midday trading on Friday, hitting $0.24. 45,440,418 shares of the company traded hands, compared to its average volume of 15,009,065. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $22.14. The firm has a market cap of $44.95 million, a P/E ratio of 0.00 and a beta of 2.23. The stock has a 50-day moving average price of $0.17 and a 200 day moving average price of $0.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Saturday, December 7th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.